SAN DIEGO, March 25, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that it intends to offer shares of its Class A common stock, par value $0.0001 per share (“Class A Common Stock”) and, in lieu of common stock to certain investors that so elect, pre-funded warrants to purchase additional shares of its Class A Common Stock in an underwritten public offering (t ...

Financial Performance - Prime Medicine Inc. reported a net loss of $201.1 million for the year 2025, with R&D expenses at $160.6 million, indicating a stable investment in research despite financial losses [1] - The company ended the year with $191.4 million in cash, cash equivalents, and investments, providing a financial runway into 2027 [1] Strategic Focus - The company is shifting its focus toward its in vivo liver franchise, specifically targeting Wilson Disease and Alpha-1 Antitrypsin Deficiency [2] - Prime Medicine plans to submit an IND or CTA for the Wilson Disease program in the first half of 2026, followed by a mid-2026 submission for the Alpha-1 Antitrypsin Deficiency program [2] Clinical Developments - Prime Medicine is actively engaging with the FDA to pursue an accelerated approval pathway for its CGD candidate, PM359, which has shown positive Phase 1/2 data [3] - The company intends to submit a BLA for PM359 once final alignment with the FDA is achieved, potentially making it the first Prime Edited therapy available to patients [3] Partnerships and Support - The company is progressing its Cystic Fibrosis program with support from the Cystic Fibrosis Foundation and continues its CAR-T partnership with Bristol Myers Squibb [2]

Core Insights - Eli Lilly is currently the leading manufacturer of GLP-1 drugs, experiencing a significant stock price increase of 225% over the past three years, which has resulted in a high price-to-earnings ratio of 49 and a low yield of 0.6% [2] Group 1: Current Performance - Sales of Mounjaro increased by 99% in 2025, while Zepbound sales surged by 175%, indicating strong performance in the GLP-1 market [3] - Mounjaro and Zepbound together accounted for 56% of Eli Lilly's total sales in 2025, highlighting the company's reliance on these two products for revenue [4] Group 2: Future Challenges - The company faces a potential "patent cliff," where the expiration of patent protection for Mounjaro and Zepbound could lead to a significant decline in sales as generic alternatives enter the market [5] Group 3: Strategic Initiatives - To mitigate long-term risks, Eli Lilly is investing its GLP-1 revenue into new opportunities, including a partnership with Seamless Therapeutics to develop gene editing technology for treating hearing loss [6] - The company has also agreed to acquire Ventyx Biosciences, which is focused on developing oral treatments for inflammation, further diversifying its portfolio [7]

Core Insights - Cibus, Inc. will report its second quarter 2025 financial results on August 14, 2025, with a conference call scheduled for 4:30 p.m. ET to discuss these results and other updates [1][2]. Company Overview - Cibus is a leading agricultural technology company focused on developing and licensing plant traits to seed companies, utilizing proprietary high-throughput gene editing technology [4]. - The company addresses critical productivity and sustainability challenges for farmers, particularly diseases and pests, which the United Nations estimates cost the global economy approximately $300 billion annually [4]. - Cibus is not a seed company but a technology company that licenses its innovations to seed companies in exchange for royalties on seed sales [4].

Core Insights - Cibus, Inc. has successfully closed a public offering of 15,714,285 shares of Class A Common Stock at a price of $1.75 per share, raising gross proceeds of $27.5 million [1][2] Company Overview - Cibus is a leading agricultural biotechnology company focused on developing plant traits through proprietary gene editing technologies, addressing productivity and sustainability challenges for farmers [6] - The company is not a seed company but a technology company that licenses developed crop traits to seed companies in exchange for royalties on seed sales [6] Use of Proceeds - The net proceeds from the offering will be utilized for the development of weed management productivity traits in rice, as well as for working capital and general corporate purposes [2] Offering Details - The offering was conducted under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission, with A.G.P./Alliance Global Partners acting as the sole placement agent [3][4]

Core Viewpoint - Cibus, Inc. has announced a public offering of 15,714,285 shares of its Class A Common Stock at a price of $1.75 per share, aiming to raise approximately $27.5 million for further development and working capital [1][2]. Company Overview - Cibus is a leading agricultural biotechnology company specializing in gene editing technologies to develop plant traits in seeds, focusing on productivity traits for major crops [6]. - The company addresses significant agricultural challenges, including diseases and pests, which the United Nations estimates cost the global economy around $300 billion annually [6]. - Cibus operates as a technology company rather than a seed company, licensing its developed traits to seed companies for royalties on seed sales [6]. Offering Details - The offering consists solely of shares sold by Cibus, with gross proceeds expected to be approximately $27.5 million before expenses [2]. - The offering is anticipated to close on or about June 6, 2025, pending customary closing conditions [2]. - A.G.P./Alliance Global Partners is acting as the sole placement agent for this offering [3]. Use of Proceeds - The net proceeds from the offering will be utilized to fund the development of weed management productivity traits in rice and for general corporate purposes [2]. Regulatory Information - The offering is made under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission, with a prospectus supplement to be filed [4].

Group 1 - Cibus, Inc. is a leading agricultural biotechnology company focused on gene editing technologies to develop specific traits in seeds [1][3] - The company will present its advancements in gene-editing technology, regulatory developments, and commercialization strategy at the AGP Annual Virtual Healthcare Company Showcase [2][3] - Cibus addresses significant productivity and sustainability challenges for farmers, with an estimated global economic cost of $300 billion annually due to diseases and pests [3] Group 2 - Cibus operates as a technology company rather than a seed company, licensing traits to seed companies in exchange for royalties [3] - The company has a pipeline of five productivity traits, focusing on weed management in rice, pod shatter reduction, and disease resistance [3] - Cibus aims to develop and commercialize plant traits more efficiently and cost-effectively than conventional breeding methods [3]

Core Insights - Cibus, Inc. will report its fourth quarter 2024 financial results on March 20, 2025, with a conference call scheduled for 4:30 p.m. ET to discuss these results and other updates [1][2] Company Overview - Cibus is a leading agricultural biotechnology company specializing in proprietary gene editing technologies to develop specific genetic traits in seeds [1][3] - The company focuses on addressing critical productivity and sustainability challenges for farmers, particularly diseases and pests, which cost the global economy approximately $300 billion annually according to the United Nations [3] - Cibus operates as a technology company rather than a seed company, licensing traits to seed companies in exchange for royalties on seed sales [3] - The long-term focus of Cibus is on productivity traits for major global row crops such as canola, corn, rice, soybean, and wheat [3] - Cibus has developed a pipeline of five productivity traits, including weed management in rice, pod shatter reduction, and sclerotinia resistance, which are its near-term focus areas [3]